Obagi Medical, a subsidiary of Waldencast plc, announced the launch of its new Retinol + PHA Refining Night Cream. This advanced formulation combines Entrapped Retinol with Polyhydroxy Acid (PHA) Gluconolactone to optimize skin renewal and enhance cell turnover while reinforcing the skin barrier. The product is designed to deliver a refined, smoother, and more even complexion.
The innovative formula features PHA, a next-generation exfoliant with a larger molecular structure than AHAs and BHAs, allowing for effective resurfacing with minimal irritation. Entrapped Retinol provides a slow-release delivery, gradually delivering retinol into multiple layers of the skin over time, maximizing efficacy while minimizing irritation. This makes it suitable for beginners and those with sensitive skin.
Fortified with eight additional dermatologically recognized ingredients, the cream supports hydration, minimizes irritation, and enhances skin resilience. A four-week clinical study demonstrated significant improvements in skin texture and tone among participants. The Retinol + PHA Refining Night Cream, priced at $135, is available through partnering professional channels and on Obagi.com starting May 5, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.